InvestorsHub Logo
Followers 78
Posts 4681
Boards Moderated 0
Alias Born 02/20/2012

Re: Dankshydro post# 3538

Wednesday, 04/22/2020 2:09:09 PM

Wednesday, April 22, 2020 2:09:09 PM

Post# of 3867
Alliance Global Partners analyst James Molloy initiated coverage of Genprex with a Buy rating and $8 price target. The analyst views the Fast Track Designation for the company's lead asset Oncoprex as a "significant positive." The company is using gene therapy to "change the game in immuno-oncology," Molloy tells investors in a research note

Read more at:
https://thefly.com/landingPageNews.php?id=3077096
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent GNPX News